osimertinib

Osimertinib is an oral, third-generation, small molecule tyrosine kinase inhibitor that selectively targets the epidermal growth factor receptor (EGFR) with activating mutations and the T790M resistance mutation. It is primarily used for the treatment of non-small cell lung cancer (NSCLC) in patients whose tumors harbor specific EGFR mutations, including exon 19 deletions, exon 21 L858R substitutions, or T790M mutations. Osimertinib works by irreversibly binding to mutant forms of EGFR and inhibiting downstream signaling pathways that promote tumor cell proliferation and survival. Developed by AstraZeneca, it has become a standard therapy for first-line treatment of metastatic NSCLC with EGFR mutations as well as for adjuvant therapy after tumor resection to prevent recurrence[1][2][3][4][5].

Brand names

Tagrisso

Other names

osimertinib mesylate